AstraZeneca's Fasenra fails its second COPD trial, handing rival GSK a win

CG image of AstraZeneca's HQ
AstraZeneca's Fasenra has now failed both its phase 3 COPD studies. (AstraZeneca)

AstraZeneca’s hopes for expanding severe asthma drug Fasenra into chronic obstructive pulmonary disease are officially lost.

Wednesday, the British drugmaker said the therapy had flopped a phase 3 trial—its second of two—testing the drug in patients with moderate to very severe COPD.

Fasenra missed the primary endpoint of the study, dubbed Terranova, failing to significantly cut down on episodes when symptoms suddenly worsened.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: AstraZeneca's respiratory rivalry with GlaxoSmithKline takes a hit with Fasenra's phase 3 fail

AstraZeneca made a similar announcement earlier this month after Fasenra fell short in a separate phase 3 study, Galathea, though at the time it said it would wait for the Terranova results to roll in before making any decisions.

Now, though, there’s not much left to do besides “analyze the complete data sets … to further understand these results,” R&D chief Sean Bohen said in a statement, adding that, “These results are disappointing.”

Fasenra’s dashed COPD prospects mark a big setback for AstraZeneca, which was looking to give respiratory rival GlaxoSmithKline a run for its money. Though GSK had a two-year head start with Fasenra’s in-class rival, Nucala, AZ execs hoped Fasenra’s less-frequent dosing could help it poach market share. It is dosed every eight weeks after the first three doses, a less frequent schedule than Nucala.

RELATED: AstraZeneca goes to battle with GSK with nod for Nucala challenger Fasenra

Unlike Fasenra, though, Nucala has already shown it can improve exacerbation rates. In a phase 3 study, the drug beat out placebo at paring down the frequency of moderate and severe episodes in patients with higher blood eosinophil counts, a biomarker targeted by this class of drugs. Now, Glaxo is waiting for a decision from the FDA—and if it gets a green light, it’ll give the company a major edge over AstraZeneca.

GSK is getting ahead outside of asthma and COPD, too. Back in December, it picked up an FDA go-ahead for Nucala to treat eosinophilic granulomatosis with polyangiitis (EGPA), a chronic rare disease caused by inflammation in the walls of blood vessels.

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.